Frost & Sullivan has awarded Barco with the Customer Value Award for VOXAR 3D, a portfolio of advanced visualisation software and clinical applications. According to Frost & Sullivan, Barco's VOXAR 3D software provides customers with the best value for their investment in an advanced visualisation solution for a PACS environment.
Frost & Sullivan granted the award to Barco because of VOXAR 3D's cost-effective deployment options, which provide unlimited access to advanced visualisation toolsets and clinical application modules everywhere users need them throughout the hospital.
In addition, Barco received the Award because it has extended the value of its VOXAR 3D software with the introduction of specific clinical applications. In 2005, Barco received FDA 510(k) clearance from the U.S. Food and Drug Administration for two innovative additions to the VOXAR 3D product line. VOXAR 3D VESSEL METRIX was approved for quantitative vessel analysis of CT and MR angiographic studies; VOXAR COLONSCREEN was approved for reading CT colonography studies of symptomatic and asymptomatic patients. These FDA approved clinical application modules add greater value to the VOXAR 3D product line by providing dedicated, clinical-focused tools for specific imaging applications.